Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia

Andrew Koh, Philip A. Pizzo

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

For over 30 years, fever and neutropenia in cancer patients has been treated with the utmost urgency, necessitating inpatient evaluation and immediate initiation of empirical broad-spectrum parenteral (IV) antibiotics. This practice is based on the recognition that delays in starting antibiotic therapy in febrile neutropenic patients have been associated with life-threatening infections and sometimes fatal consequences. Over the past decade, it has become evident that neutropenic cancer patients are not a homogeneous group and that practice guidelines may vary on their risk status. In fact, attempts have been made to stratify patients into high-risk and low-risk groups and differentiate treatment options respectively. Recent studies suggest that those neutropenic cancer patients who are at low risk may even be successfully treated with oral therapy, thus opening the possibility for ambulatory or home-based management. Oral antibiotic therapy, especially if safely delivered at home, offers a number of advantages including lower cost, improved quality of life (although the impact of shifting the burden of care from the hospital to the home setting on the patient, parent or care provider needs careful assessment) and a decreased risk for nosocomial infection.

Original languageEnglish (US)
Pages (from-to)420-433
Number of pages14
JournalCancer Investigation
Volume20
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Neutropenia
Fever
Anti-Bacterial Agents
Neoplasms
Therapeutics
Group Practice
Needs Assessment
Cross Infection
Practice Guidelines
Inpatients
Quality of Life
Costs and Cost Analysis
Infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia. / Koh, Andrew; Pizzo, Philip A.

In: Cancer Investigation, Vol. 20, No. 3, 2002, p. 420-433.

Research output: Contribution to journalArticle

@article{48a0c905d2354a838cdf8d25186693bf,
title = "Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia",
abstract = "For over 30 years, fever and neutropenia in cancer patients has been treated with the utmost urgency, necessitating inpatient evaluation and immediate initiation of empirical broad-spectrum parenteral (IV) antibiotics. This practice is based on the recognition that delays in starting antibiotic therapy in febrile neutropenic patients have been associated with life-threatening infections and sometimes fatal consequences. Over the past decade, it has become evident that neutropenic cancer patients are not a homogeneous group and that practice guidelines may vary on their risk status. In fact, attempts have been made to stratify patients into high-risk and low-risk groups and differentiate treatment options respectively. Recent studies suggest that those neutropenic cancer patients who are at low risk may even be successfully treated with oral therapy, thus opening the possibility for ambulatory or home-based management. Oral antibiotic therapy, especially if safely delivered at home, offers a number of advantages including lower cost, improved quality of life (although the impact of shifting the burden of care from the hospital to the home setting on the patient, parent or care provider needs careful assessment) and a decreased risk for nosocomial infection.",
author = "Andrew Koh and Pizzo, {Philip A.}",
year = "2002",
doi = "10.1081/CNV-120001186",
language = "English (US)",
volume = "20",
pages = "420--433",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia

AU - Koh, Andrew

AU - Pizzo, Philip A.

PY - 2002

Y1 - 2002

N2 - For over 30 years, fever and neutropenia in cancer patients has been treated with the utmost urgency, necessitating inpatient evaluation and immediate initiation of empirical broad-spectrum parenteral (IV) antibiotics. This practice is based on the recognition that delays in starting antibiotic therapy in febrile neutropenic patients have been associated with life-threatening infections and sometimes fatal consequences. Over the past decade, it has become evident that neutropenic cancer patients are not a homogeneous group and that practice guidelines may vary on their risk status. In fact, attempts have been made to stratify patients into high-risk and low-risk groups and differentiate treatment options respectively. Recent studies suggest that those neutropenic cancer patients who are at low risk may even be successfully treated with oral therapy, thus opening the possibility for ambulatory or home-based management. Oral antibiotic therapy, especially if safely delivered at home, offers a number of advantages including lower cost, improved quality of life (although the impact of shifting the burden of care from the hospital to the home setting on the patient, parent or care provider needs careful assessment) and a decreased risk for nosocomial infection.

AB - For over 30 years, fever and neutropenia in cancer patients has been treated with the utmost urgency, necessitating inpatient evaluation and immediate initiation of empirical broad-spectrum parenteral (IV) antibiotics. This practice is based on the recognition that delays in starting antibiotic therapy in febrile neutropenic patients have been associated with life-threatening infections and sometimes fatal consequences. Over the past decade, it has become evident that neutropenic cancer patients are not a homogeneous group and that practice guidelines may vary on their risk status. In fact, attempts have been made to stratify patients into high-risk and low-risk groups and differentiate treatment options respectively. Recent studies suggest that those neutropenic cancer patients who are at low risk may even be successfully treated with oral therapy, thus opening the possibility for ambulatory or home-based management. Oral antibiotic therapy, especially if safely delivered at home, offers a number of advantages including lower cost, improved quality of life (although the impact of shifting the burden of care from the hospital to the home setting on the patient, parent or care provider needs careful assessment) and a decreased risk for nosocomial infection.

UR - http://www.scopus.com/inward/record.url?scp=0036247164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036247164&partnerID=8YFLogxK

U2 - 10.1081/CNV-120001186

DO - 10.1081/CNV-120001186

M3 - Article

C2 - 12025236

AN - SCOPUS:0036247164

VL - 20

SP - 420

EP - 433

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -